NEW YORK, July 25, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Allarity and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On February 6 ...

文章核心观点 - 公司正在推动股东批准进行反向股票拆分,以避免公司股票被纳斯达克交易所摘牌[1][2][5] - 公司还建议股东批准减少公司授权股份数量,并呼吁之前反对这些事项的投资者重新考虑他们的决定[3][4] 根据相关目录分别进行总结 公司推动反向股票拆分的原因 - 公司股价目前远低于纳斯达克交易所要求的最低1美元交易价格[5] - 公司表示,未能获得批准进行反向股票拆分可能会妨碍管理层执行其战略,并可能阻碍依赖发行普通股的业务发展计划[4] - 反向股票拆分可以巩固公司整体价值,并保持每位股东的相对持股比例不变[4] 公司股价及交易情况 - 公司股价周三上涨4.6%,成交量达5900万股,远高于日均700万股[6] - 公司鼓励投资者关注更多最新的股市新闻[6][7]

ATLANTA, July 24, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR) complied with federal securities laws. On July 22, 2024, Allarity disclosed that it received a Wells Notice from the SEC concerning "the Company's disclosures regarding meetings with the United States Food and Drug Administration (the "FDA") regarding the Company's NDA for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021." Followin ...

Boston (July 24, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, encourages its stockholders to participate actively in the upcoming annual meeting of stockholders scheduled on July 26, 2024. The Company's Board of Directors has put a proposal before stockholders for a reverse stock split. Allarity has requested approval of the reverse stock split to regain and sustain compl ...

  Current Cash Balance of $20 million Expected to Provide Runway Into 2026Allarity to Pause Use of ATMCap Table Successfully Cleaned UpAllarity's Stenoparib Shows Extended Duration of Phase 2 Clinical Benefit Boston (July 22, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today outlines the Company's progress in 2024 and future objectives. Led by New Management Allarity has ...

  Current Cash Balance of $20 million Expected to Provide Runway Into 2026Allarity to Pause Use of ATMCap Table Successfully Cleaned UpAllarity’s Stenoparib Shows Extended Duration of Phase 2 Clinical Benefit Boston (July 22, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today outlines the Company’s progress in 2024 and future objectives. Led by New Management Allarity ha ...

Boston (June 27, 2024) — Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that it received notice from the NASDAQ Stock Market ("NASDAQ") that it was granted a hearing before a Nasdaq Hearings Panel (the "Panel"). This upcoming hearing, occurring in approximately 5 weeks, is scheduled for the Company to present its plan for regaining compliance following Nasdaq's no ...

Boston (May 20, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that it has received formal written notice from The Nasdaq Stock Market, LLC's Office of General Counsel ("Nasdaq") that the Company has regained compliance with the minimum stockholders' equity requirement as set forth in Nasdaq Listing Rule 5550(b)(1) (the "Equity Rule"). This confirmation foll ...

财务表现 - Allarity Therapeutics在2024年第一季度取得了显著的财务成果和运营亮点[1] - Allarity Therapeutics的研发费用在2024年第一季度达到了220万美元，较去年同期增加了743,000美元，主要是由于制造成本增加和支付给Eisai Co., Ltd.的扩展费用[10] - Allarity Therapeutics的总营运支出在2024年第一季度为424万美元，较去年同期增加了572,000美元[20] - Allarity Therapeutics在2024年第一季度的净亏损为380万美元，较去年同期增加了400,000美元[13] - Allarity Therapeutics的现金余额为312,000美元，其他流动资产为110,000美元，预付费用为542,000美元，税收抵免为1,331,000美元，总流动资产为2,295,000美元[19] - Allarity Therapeutics的总资产为11,969,000美元，总负债为18,440,000美元，股东权益为6,471,000美元[19] - Allarity Therapeutics的股东权益中，附加支付资本为90,699,000美元，累计赤字为98,294,000美元[19] 净亏损情况 - Allarity Therapeutics在2024年第一季度的净亏损为384.3万美元，较去年同期增加了48.8万美元[20]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Delaware 87-2147982 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share ALLR The Nasdaq Stock Market LLC FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRA ...